Sunday, June 12, 2011

DR. REDDY’S LABS LAUNCHES THREE GENERIC PRODUCTS IN USA


Dr Reddy's Laboratories announced on Jun. 6, 2011 that it launched three generic drugs in the US market. The drugs are used to treat central nervous system disorders and were all approved by the US drug regulator in the last two weeks.

Donepezil Hydrochloride tablets is a remake of Japan based Eisai Pharma's Aricept and its sale in the US alone fetched the company over $ 2 billion for the financial year 2011.

The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Donepezil HCl tablets on May 31, 2011. The drug is available in 5mg and 10mg strengths in 30, 90 and 500 count bottles.

The second drug released- Venlafaxine Hydrochloride Extended Release capsules- is a copy cat of Wyeth's Effexor XR ® and is used to treat depression and social anxiety. Dr. Reddy’s will be competing with bigger generic players like Mylan and Teva who are their version of this drug in the US.

The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Venlafaxine Hydrochloride Extended Release Capsules on May 05, 2011.

Effexor accounted for $ 2.3 billion of Wyeth's total sales. All three strengths of Dr. Reddy’s Venlafaxine Hydrochloride Extended Release Capsules are available in 30, 90 and 500 count bottles.

Letrozole tablets, available in 2.5 mg potency, are a cheaper (bioequivalent generic) version of Novartis' Femara ® and are used to treat menopausal disorders.

The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Letrozole tablets, USP on June 3, 2011. According to IMS Health, the pharmaceutical intelligence firm, Femara clocked in sales of $ 720 million in US in the last financial year. Dr. Reddy’s Letrozole tablets, USP are available in 30 count bottles.

0 comments:

Post a Comment